Company Overview of Organovo Holdings, Inc.
Organovo Holdings, Inc., a development-stage company, focuses on developing and commercializing functional human tissues that could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The company is developing a suite of standardized and three-dimensional human tissues for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion, and drug metabolism and pharmacokinetics; customized human tissues as living, dynamic models of human biology or disease, for use in drug discovery and development; and three-...
6275 Nancy Ridge Drive
San Diego, CA 92121
Founded in 2007
Key Executives for Organovo Holdings, Inc.
Total Annual Compensation: $362.9K
Chief Financial Officer
Total Annual Compensation: $289.1K
Chief Strategy Officer
Total Annual Compensation: $289.8K
Chief Technology Officer and Executive Vice President of Research & Development
Total Annual Compensation: $289.1K
Executive Vice President of Commercial Operations
Total Annual Compensation: $268.5K
Compensation as of Fiscal Year 2014.
Organovo Holdings, Inc. Key Developments
Organovo Holdings, Inc. Announces Commercial Release of the exVive3D(TM) Human Liver Tissue
Nov 18 14
Organovo Holdings, Inc. announced the full commercial release of the exVive3D(TM) Human Liver Tissue for preclinical drug discovery testing. Initially, clients will be able to access the technology through Organovo's contract research services program. This model is intended to provide human-specific data to aid in the prediction of liver tissue toxicity or ADME outcomes in later stage preclinical drug discovery programs. Organovo's exVive3D Liver Models are bioprinted, living 3D human liver tissues consisting of primary human hepatocytes, stellate, and endothelial cell types, which are found in native human liver. The exVive3D Liver Models are created using Organovo's proprietary 3D bioprinting technology that builds functional living tissues containing precise and reproducible architecture. The tissues are functional and stable for at least 42 days, which enables assessment of drug effects over study durations that well beyond those offered by industry-standard 2D liver cell culture systems. The exVive 3D Liver has successfully differentiated between structurally related compounds with known toxic and non-toxic profiles in human beings, and the model has also been employed successfully in the detection of metabolites at extended time points in vitro. Importantly, the configuration of the bioprinted liver tissues enables both biochemical and histologic data to be collected so that a customer can investigate compound responses at multiple levels. The durability and functionality of the 3D liver product enable the assessment of the effects of low dose or repeated dosing regimens across a spectrum of biochemical, molecular, and histologic end points. All testing will be performed at Organovo's facility by the Company's laboratory services tissue experts.
Organovo Holdings, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended September 30, 2014
Nov 10 14
Organovo Holdings, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended September 30, 2014. For the quarter, the company reported total revenues of $50,000 against $23,000 a year ago. Loss from operations was $8,956,000 against $5,602,000 a year ago. Net loss was $8,858,000 or $0.11 basic and diluted per share against $10,386,000 or $0.14 basic and diluted per share a year ago. Majority of revenues were derived from collaborative research agreements.
For the six months, the company reported total revenues of $149,000 against $129,000 a year ago. Loss from operations was $15,366,000 against $9,336,000 a year ago. Net loss was $15,291,000 or $0.19 basic and diluted per share against $14,157,000 or $0.21 basic and diluted per share a year ago. Net cash used in operating activities was $9,677,000 against $6,256,000 a year ago. Purchases of fixed assets were $576,000 against $176,000 a year ago. This increase in cash usage can be attributed to a $6.0 million increase in operating expenses, partially offset by an overall increase of $2.0 million of non-cash expenses included in operations, including stock-based compensation, depreciation and amortization, as well as changes in working capital. Majority of revenues were derived from collaborative research agreements.
Organovo Holdings, Inc. Presents at Stem Cell Meeting on the Mesa Partnering Forum, Oct-07-2014 through Oct-09-2014
Oct 4 14
Organovo Holdings, Inc. Presents at Stem Cell Meeting on the Mesa Partnering Forum, Oct-07-2014 through Oct-09-2014. Venue: Estancia La Jolla Hotel & Spa, 9700 North Torrey Pines Road, La Jolla, CA 92037, United States. Presentation Date & Speakers: Oct-07-2014. Oct-09-2014, Sharon Collins Presnell, Chief Technology Officer and Executive Vice President of Research & Development.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|